Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis
Patients with persistent ulcerative colitis (UC) are at a higher risk of developing colitis-associated cancer (CAC). Previous studies have reported that intestinal microbiota disturbance plays an important role in the process of CAC development in patients with UC, indicating that targeted intervent...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2021-12, Vol.523, p.170-181 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | |
| container_start_page | 170 |
| container_title | Cancer letters |
| container_volume | 523 |
| creator | Shao, Xinyu Sun, Shishuo Zhou, Yuqing Wang, Huiyu Yu, Yang Hu, Tong Yao, Yizhou Zhou, Chunli |
| description | Patients with persistent ulcerative colitis (UC) are at a higher risk of developing colitis-associated cancer (CAC). Previous studies have reported that intestinal microbiota disturbance plays an important role in the process of CAC development in patients with UC, indicating that targeted intervention of intestinal microbiota and its metabolites may be a potential therapeutic strategy. Gut microbiota in the process of colorectal cancer development in UC patients was analyzed using the gutMEGA database and verified in fecal samples. The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development. However, gavage transplantation with B. fragilis can effectively reverse the effects of BSAB. In the intestinal tract, B. fragilis promotes the secretion of short-chain fatty acids (SCFAs). Subsequently, SCFAs, especially butyrate, negatively regulate the inflammatory signaling pathway mediated by NLRP3 to inhibit the activation of macrophages and the secretion of proinflammatory mediators such as IL-18 and IL-1β, reducing the level of intestinal inflammation and restricting CAC development. In conclusion, colonization with B. fragilis has been shown to be effective in ameliorating intestinal epithelial damage caused by chronic inflammation and preventing the development of colonic tumors. Thus, it can be a therapeutic intervention strategy with good clinical application prospects.
•Colonization with B. fragilis relieves intestinal inflammation, maintains intestinal homeostasis via regulating SCFAs.•B. fragilis transplantation is effective in preventing intestinal epithelial damage and the development of CAC.•B. fragilis FMT may be an intervention therapy strategy with good clinical application prospect.•Butyrate negatively regulates the NLRP3 inflammatory pathway, to inhibit the secretion of proinflammatory mediators. |
| doi_str_mv | 10.1016/j.canlet.2021.10.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2580943516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383521005127</els_id><sourcerecordid>2580943516</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-c59e5bd6fda1b5e30bc4c3d52aad37cf00ea309da18ab45788c1f53cf6650db63</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxa0K1G4L3wAhS1y4ZBnHcf5ckGhFW6QVVBWcLWc8WbzKxsV2VvDt62hbDhw42Rr_3sz4PcbeCFgLEPWH3RrNNFJal1CKXFoDlCdsJdqmLJquhRdsBRKqQrZSnbHzGHcAoKpGnbIzWdVl0ymxYv2lwUTBO0uRD8Fs3egiDxRTcJgiRz-65GJhYvToTCLL81ikwA_O8Im2JrkDZcF2HvPVT9wPPP0k_nVzfye5-e3iK_ZyMGOk10_nBftx_fn71W2x-Xbz5erTpsBK1qlA1ZHqbT1YI3pFEnqsUFpVGmNlgwMAGQldfm1NX6mmbVEMSuJQ1wpsX8sL9v7Y9yH4X3P-gd67iDSOZiI_R12qFrpKKrGg7_5Bd34OU95uoVQnZddBpqojhcHHGGjQD8HtTfijBeglA73Txwz0ksFSzRlk2dun5nO_J_tX9Gx6Bj4eAcpuHBwFHdFRNtW6QJi09e7_Ex4BtaOalg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2585933990</pqid></control><display><type>article</type><title>Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shao, Xinyu ; Sun, Shishuo ; Zhou, Yuqing ; Wang, Huiyu ; Yu, Yang ; Hu, Tong ; Yao, Yizhou ; Zhou, Chunli</creator><creatorcontrib>Shao, Xinyu ; Sun, Shishuo ; Zhou, Yuqing ; Wang, Huiyu ; Yu, Yang ; Hu, Tong ; Yao, Yizhou ; Zhou, Chunli</creatorcontrib><description>Patients with persistent ulcerative colitis (UC) are at a higher risk of developing colitis-associated cancer (CAC). Previous studies have reported that intestinal microbiota disturbance plays an important role in the process of CAC development in patients with UC, indicating that targeted intervention of intestinal microbiota and its metabolites may be a potential therapeutic strategy. Gut microbiota in the process of colorectal cancer development in UC patients was analyzed using the gutMEGA database and verified in fecal samples. The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development. However, gavage transplantation with B. fragilis can effectively reverse the effects of BSAB. In the intestinal tract, B. fragilis promotes the secretion of short-chain fatty acids (SCFAs). Subsequently, SCFAs, especially butyrate, negatively regulate the inflammatory signaling pathway mediated by NLRP3 to inhibit the activation of macrophages and the secretion of proinflammatory mediators such as IL-18 and IL-1β, reducing the level of intestinal inflammation and restricting CAC development. In conclusion, colonization with B. fragilis has been shown to be effective in ameliorating intestinal epithelial damage caused by chronic inflammation and preventing the development of colonic tumors. Thus, it can be a therapeutic intervention strategy with good clinical application prospects.
•Colonization with B. fragilis relieves intestinal inflammation, maintains intestinal homeostasis via regulating SCFAs.•B. fragilis transplantation is effective in preventing intestinal epithelial damage and the development of CAC.•B. fragilis FMT may be an intervention therapy strategy with good clinical application prospect.•Butyrate negatively regulates the NLRP3 inflammatory pathway, to inhibit the secretion of proinflammatory mediators.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2021.10.002</identifier><identifier>PMID: 34627951</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Animals ; Antibiotics ; Antibodies ; Apoptosis ; Bacteria ; Bacteroides fragilis ; Bacteroides fragilis - physiology ; Binding sites ; Butyrate ; Butyrates - pharmacology ; Cancer therapies ; Cell activation ; Chemotherapy ; Colitis, Ulcerative - complications ; Colitis-associated cancer ; Colitis-Associated Neoplasms - prevention & control ; Colon cancer ; Colorectal cancer ; Colorectal carcinoma ; Drug resistance ; Dysbiosis ; Fatty acids ; Fatty Acids, Volatile - metabolism ; Feces ; Gastrointestinal Microbiome - physiology ; Humans ; IL-1β ; Inflammation ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Interleukin 18 ; Intestinal microflora ; Intestine ; Macrophages ; Macrophages - drug effects ; Macrophages - physiology ; Male ; Mice ; Mice, Inbred C57BL ; Microbiota ; NLR Family, Pyrin Domain-Containing 3 Protein - physiology ; Patients ; Proinflammatory mediators ; Proteins ; Radiation therapy ; Remission (Medicine) ; Signal transduction ; Transplantation ; Tumors ; Ulcerative colitis</subject><ispartof>Cancer letters, 2021-12, Vol.523, p.170-181</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</rights><rights>2021. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-c59e5bd6fda1b5e30bc4c3d52aad37cf00ea309da18ab45788c1f53cf6650db63</citedby><cites>FETCH-LOGICAL-c436t-c59e5bd6fda1b5e30bc4c3d52aad37cf00ea309da18ab45788c1f53cf6650db63</cites><orcidid>0000-0001-8954-639X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2021.10.002$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34627951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shao, Xinyu</creatorcontrib><creatorcontrib>Sun, Shishuo</creatorcontrib><creatorcontrib>Zhou, Yuqing</creatorcontrib><creatorcontrib>Wang, Huiyu</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Hu, Tong</creatorcontrib><creatorcontrib>Yao, Yizhou</creatorcontrib><creatorcontrib>Zhou, Chunli</creatorcontrib><title>Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Patients with persistent ulcerative colitis (UC) are at a higher risk of developing colitis-associated cancer (CAC). Previous studies have reported that intestinal microbiota disturbance plays an important role in the process of CAC development in patients with UC, indicating that targeted intervention of intestinal microbiota and its metabolites may be a potential therapeutic strategy. Gut microbiota in the process of colorectal cancer development in UC patients was analyzed using the gutMEGA database and verified in fecal samples. The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development. However, gavage transplantation with B. fragilis can effectively reverse the effects of BSAB. In the intestinal tract, B. fragilis promotes the secretion of short-chain fatty acids (SCFAs). Subsequently, SCFAs, especially butyrate, negatively regulate the inflammatory signaling pathway mediated by NLRP3 to inhibit the activation of macrophages and the secretion of proinflammatory mediators such as IL-18 and IL-1β, reducing the level of intestinal inflammation and restricting CAC development. In conclusion, colonization with B. fragilis has been shown to be effective in ameliorating intestinal epithelial damage caused by chronic inflammation and preventing the development of colonic tumors. Thus, it can be a therapeutic intervention strategy with good clinical application prospects.
•Colonization with B. fragilis relieves intestinal inflammation, maintains intestinal homeostasis via regulating SCFAs.•B. fragilis transplantation is effective in preventing intestinal epithelial damage and the development of CAC.•B. fragilis FMT may be an intervention therapy strategy with good clinical application prospect.•Butyrate negatively regulates the NLRP3 inflammatory pathway, to inhibit the secretion of proinflammatory mediators.</description><subject>Animals</subject><subject>Antibiotics</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Bacteria</subject><subject>Bacteroides fragilis</subject><subject>Bacteroides fragilis - physiology</subject><subject>Binding sites</subject><subject>Butyrate</subject><subject>Butyrates - pharmacology</subject><subject>Cancer therapies</subject><subject>Cell activation</subject><subject>Chemotherapy</subject><subject>Colitis, Ulcerative - complications</subject><subject>Colitis-associated cancer</subject><subject>Colitis-Associated Neoplasms - prevention & control</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Drug resistance</subject><subject>Dysbiosis</subject><subject>Fatty acids</subject><subject>Fatty Acids, Volatile - metabolism</subject><subject>Feces</subject><subject>Gastrointestinal Microbiome - physiology</subject><subject>Humans</subject><subject>IL-1β</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Interleukin 18</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Macrophages</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - physiology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiota</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein - physiology</subject><subject>Patients</subject><subject>Proinflammatory mediators</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Remission (Medicine)</subject><subject>Signal transduction</subject><subject>Transplantation</subject><subject>Tumors</subject><subject>Ulcerative colitis</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxa0K1G4L3wAhS1y4ZBnHcf5ckGhFW6QVVBWcLWc8WbzKxsV2VvDt62hbDhw42Rr_3sz4PcbeCFgLEPWH3RrNNFJal1CKXFoDlCdsJdqmLJquhRdsBRKqQrZSnbHzGHcAoKpGnbIzWdVl0ymxYv2lwUTBO0uRD8Fs3egiDxRTcJgiRz-65GJhYvToTCLL81ikwA_O8Im2JrkDZcF2HvPVT9wPPP0k_nVzfye5-e3iK_ZyMGOk10_nBftx_fn71W2x-Xbz5erTpsBK1qlA1ZHqbT1YI3pFEnqsUFpVGmNlgwMAGQldfm1NX6mmbVEMSuJQ1wpsX8sL9v7Y9yH4X3P-gd67iDSOZiI_R12qFrpKKrGg7_5Bd34OU95uoVQnZddBpqojhcHHGGjQD8HtTfijBeglA73Txwz0ksFSzRlk2dun5nO_J_tX9Gx6Bj4eAcpuHBwFHdFRNtW6QJi09e7_Ex4BtaOalg</recordid><startdate>20211228</startdate><enddate>20211228</enddate><creator>Shao, Xinyu</creator><creator>Sun, Shishuo</creator><creator>Zhou, Yuqing</creator><creator>Wang, Huiyu</creator><creator>Yu, Yang</creator><creator>Hu, Tong</creator><creator>Yao, Yizhou</creator><creator>Zhou, Chunli</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8954-639X</orcidid></search><sort><creationdate>20211228</creationdate><title>Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis</title><author>Shao, Xinyu ; Sun, Shishuo ; Zhou, Yuqing ; Wang, Huiyu ; Yu, Yang ; Hu, Tong ; Yao, Yizhou ; Zhou, Chunli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-c59e5bd6fda1b5e30bc4c3d52aad37cf00ea309da18ab45788c1f53cf6650db63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antibiotics</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Bacteria</topic><topic>Bacteroides fragilis</topic><topic>Bacteroides fragilis - physiology</topic><topic>Binding sites</topic><topic>Butyrate</topic><topic>Butyrates - pharmacology</topic><topic>Cancer therapies</topic><topic>Cell activation</topic><topic>Chemotherapy</topic><topic>Colitis, Ulcerative - complications</topic><topic>Colitis-associated cancer</topic><topic>Colitis-Associated Neoplasms - prevention & control</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Drug resistance</topic><topic>Dysbiosis</topic><topic>Fatty acids</topic><topic>Fatty Acids, Volatile - metabolism</topic><topic>Feces</topic><topic>Gastrointestinal Microbiome - physiology</topic><topic>Humans</topic><topic>IL-1β</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Interleukin 18</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Macrophages</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - physiology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiota</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein - physiology</topic><topic>Patients</topic><topic>Proinflammatory mediators</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Remission (Medicine)</topic><topic>Signal transduction</topic><topic>Transplantation</topic><topic>Tumors</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shao, Xinyu</creatorcontrib><creatorcontrib>Sun, Shishuo</creatorcontrib><creatorcontrib>Zhou, Yuqing</creatorcontrib><creatorcontrib>Wang, Huiyu</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Hu, Tong</creatorcontrib><creatorcontrib>Yao, Yizhou</creatorcontrib><creatorcontrib>Zhou, Chunli</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shao, Xinyu</au><au>Sun, Shishuo</au><au>Zhou, Yuqing</au><au>Wang, Huiyu</au><au>Yu, Yang</au><au>Hu, Tong</au><au>Yao, Yizhou</au><au>Zhou, Chunli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2021-12-28</date><risdate>2021</risdate><volume>523</volume><spage>170</spage><epage>181</epage><pages>170-181</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Patients with persistent ulcerative colitis (UC) are at a higher risk of developing colitis-associated cancer (CAC). Previous studies have reported that intestinal microbiota disturbance plays an important role in the process of CAC development in patients with UC, indicating that targeted intervention of intestinal microbiota and its metabolites may be a potential therapeutic strategy. Gut microbiota in the process of colorectal cancer development in UC patients was analyzed using the gutMEGA database and verified in fecal samples. The abundance of Bacteroides fragilis reduced significantly in the process of colitis associated cancer development. Broad-spectrum antibiotics (BSAB) intervene with the intestinal microbiota of mice and accelerate the process of colon cancer development. However, gavage transplantation with B. fragilis can effectively reverse the effects of BSAB. In the intestinal tract, B. fragilis promotes the secretion of short-chain fatty acids (SCFAs). Subsequently, SCFAs, especially butyrate, negatively regulate the inflammatory signaling pathway mediated by NLRP3 to inhibit the activation of macrophages and the secretion of proinflammatory mediators such as IL-18 and IL-1β, reducing the level of intestinal inflammation and restricting CAC development. In conclusion, colonization with B. fragilis has been shown to be effective in ameliorating intestinal epithelial damage caused by chronic inflammation and preventing the development of colonic tumors. Thus, it can be a therapeutic intervention strategy with good clinical application prospects.
•Colonization with B. fragilis relieves intestinal inflammation, maintains intestinal homeostasis via regulating SCFAs.•B. fragilis transplantation is effective in preventing intestinal epithelial damage and the development of CAC.•B. fragilis FMT may be an intervention therapy strategy with good clinical application prospect.•Butyrate negatively regulates the NLRP3 inflammatory pathway, to inhibit the secretion of proinflammatory mediators.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>34627951</pmid><doi>10.1016/j.canlet.2021.10.002</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8954-639X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2021-12, Vol.523, p.170-181 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2580943516 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antibiotics Antibodies Apoptosis Bacteria Bacteroides fragilis Bacteroides fragilis - physiology Binding sites Butyrate Butyrates - pharmacology Cancer therapies Cell activation Chemotherapy Colitis, Ulcerative - complications Colitis-associated cancer Colitis-Associated Neoplasms - prevention & control Colon cancer Colorectal cancer Colorectal carcinoma Drug resistance Dysbiosis Fatty acids Fatty Acids, Volatile - metabolism Feces Gastrointestinal Microbiome - physiology Humans IL-1β Inflammation Inflammatory bowel disease Inflammatory bowel diseases Interleukin 18 Intestinal microflora Intestine Macrophages Macrophages - drug effects Macrophages - physiology Male Mice Mice, Inbred C57BL Microbiota NLR Family, Pyrin Domain-Containing 3 Protein - physiology Patients Proinflammatory mediators Proteins Radiation therapy Remission (Medicine) Signal transduction Transplantation Tumors Ulcerative colitis |
| title | Bacteroides fragilis restricts colitis-associated cancer via negative regulation of the NLRP3 axis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T20%3A10%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bacteroides%20fragilis%20restricts%20colitis-associated%20cancer%20via%20negative%20regulation%20of%20the%20NLRP3%20axis&rft.jtitle=Cancer%20letters&rft.au=Shao,%20Xinyu&rft.date=2021-12-28&rft.volume=523&rft.spage=170&rft.epage=181&rft.pages=170-181&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2021.10.002&rft_dat=%3Cproquest_cross%3E2580943516%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2585933990&rft_id=info:pmid/34627951&rft_els_id=S0304383521005127&rfr_iscdi=true |